AnaptysBio, Inc. · NASDAQ:ANAB
AnaptysBio — Technical Presentation (2023)
12 slides from AnaptysBio's technical presentation, 2023
Slide 1: ANB032, a Novel BTLA Agonist Monoclonal Antibody: Phase 1 Results
ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study Ken Luu, Bruce Randazzo, Eric Hare, Matthew Hsu, Chris Haines, Martin Dahl, Ca
Slide 2: Disclosures
Disclosures • All authors are employees of AnaptysBio, Inc., San Diego, CA, USA 2
Slide 3: Background & Introduction
Background & Introduction • B and T cell lymphocyte attenuator (BTLA) is a co-inhibitory checkpoint receptor expressed on T cells (Th1, Th2, Th17 and Th22), B cells and dendritic cells (DC), key contributors to inflammatory diseases such as atopic dermatitis (AD) • BTLA-deficient mice showed increas
Slide 4: B and T Lymphocyte Attenuator (BTLA) Checkpoint Receptor
B and T Lymphocyte Attenuator (BTLA) Checkpoint Receptor Dendritic cell T cell activation requires DC Activation both: 1. Antigen presentation via MHC and TCR CD80/86 MHC 2. Co-stimulation via CD80/86 and CD28 CD28 TCR T cell Activation T cell HVEM, Herpes Virus Entry Mediator; MHC, major histocompa
Slide 5: B and T Lymphocyte Attenuator (BTLA) Checkpoint Receptor
B and T Lymphocyte Attenuator (BTLA) Checkpoint Receptor Dendritic cell T cell activation requires DC Activation both: 1. Antigen presentation via MHC and TCR HVEM CD80/86 MHC 2. Co-stimulation via CD80/86 and CD28 BTLA on T cell inhibits priming, activation, and expansion of inflammatory T cells CD
Slide 6: B and T Lymphocyte Attenuator (BTLA) Checkpoint Receptor
B and T Lymphocyte Attenuator (BTLA) Checkpoint Receptor Dendritic cell T cell activation requires DC Activation both: 1. Antigen presentation via BTLA MHC and TCR HVEM CD80/86 MHC 2. Co-stimulation via CD80/86 and CD28 BTLA on T cell inhibits priming, activation, and expansion of inflammatory T cel
Slide 7: Proposed Mechanism of Action for ANB032
Proposed Mechanism of Action for ANB032 Dendritic cell ANB032 binds to BTLA epitope on Augmented BTLA Agonism Th1, Th2, Th17 and Th22 T cells Fc receptor and dendritic cells • Direct agonism of BTLA • Does not block engagement of native HVEM ANB032 BTLA ligand HVEM allowing endogenous inhibitory pat
Slide 8: ANB032 Phase 1 Study Objectives
ANB032 Phase 1 Study Objectives Primary: • Assess safety and tolerability of single and multiple doses of ANB032 in healthy participants Key Secondary & Exploratory: • Characterize pharmacokinetics after single and multiple doses of ANB032 • Assess percent BLTA receptor occupancy following ANB032 ad
Slide 9: ANB032 Phase 1 Study Design
ANB032 Phase 1 Study Design SAD Cohorts Cohort 1 Cohort 2 Cohort 4 Cohort 6 Cohort 7 Cohort 9 Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Dose Level 5 Dose Level 6 IV IV IV IV IV IV Cohort 3 Cohort 5 Cohort 8 Dose Level 2 Dose Level 3 Dose Level 5 SC SC SC MAD Cohorts Cohort 10 Cohort 11 Coh
Slide 10: Results
Results Safety and Tolerability • ANB032 was well-tolerated with no dose-limiting toxicities • Most adverse events were mild-to-moderate, of short duration, dose and timing from dose independent and resolved without sequelae ― No serious adverse events were observed Pharmacokinetics • PK profile was
Slide 11: ANB032: Rapid and Sustained Pharmacodynamic Activity
ANB032: Rapid and Sustained Pharmacodynamic Activity Lower (Single) Dose Higher (Single) Dose Rapid and sustained target engagement on both T cells T Cells and B cells Full BTLA RO was observed within hours and maintained for >30 days following IV or SC dosing Moderate reduction (50%) of cell surfac
Slide 12: Summary of Phase 1 and Beyond
Summary of Phase 1 and Beyond ANB032 Phase 1: • Well-tolerated after single and multiple doses • Favorable PK profile • Demonstrated robust target engagement in healthy participants Beyond: • Atopic Dermatitis pathophysiology includes dysregulation of multiple proinflammatory pathways driven by Th1,